VBI Vaccines Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
VBIV Nasdaq 8731 https://www.vbivaccines.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for VBI Vaccines Inc

VBI Vaccines Inc.'s (NASDAQ:VBIV) Intrinsic Value Is Potentially 30% Above Its Share Price - Jun 4th, 2023 1:32 pm
VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Misses Revenue Estimates - May 15th, 2023 1:25 pm
VBI Vaccines Reports First Quarter 2023 Financial Results - May 15th, 2023 12:00 pm
Absci Corporation (ABSI) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - May 3rd, 2023 2:00 pm
VBI Vaccines, Inc. (VBIV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - May 1st, 2023 2:00 pm
VBI Vaccines Appoints Vaughn Himes to Board of Directors - Apr 25th, 2023 12:00 pm
VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans - Apr 5th, 2023 3:42 pm
VBI Vaccines Announces Cost Cutting Measures, Reverse Stock Split - Apr 4th, 2023 5:55 pm
VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split - Apr 4th, 2023 12:00 pm
VBI Vaccines Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags - Mar 15th, 2023 10:37 am
VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Misses Revenue Estimates - Mar 13th, 2023 1:15 pm
VBI Vaccines Reports Full Year 2022 Financial Results - Mar 13th, 2023 12:00 pm
VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat - Feb 23rd, 2023 1:00 pm
VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B - Feb 15th, 2023 1:00 pm
Individual investors account for 55% of VBI Vaccines Inc.'s (NASDAQ:VBIV) ownership, while private equity firms account for 25% - Jan 24th, 2023 11:16 am
VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults - Dec 8th, 2022 1:00 pm
CEPI Boosts ‘Coronavirus X’ Vaccine Search With Expanded VBI Vaccines Deal - Dec 6th, 2022 2:25 pm
VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting - Nov 22nd, 2022 1:00 pm
VBI Vaccines to Participate in Upcoming Investor Conferences - Nov 14th, 2022 1:00 pm
VBI Vaccines Announces Presentation of Data from Ongoing Phase 2a Study of VBI-1901 at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting - Nov 11th, 2022 1:00 pm